Clinical Trials Logo
  1. Home
  2. Vitrectomy
  3. NCT04501367

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Vitrectomy Clinical Trial

Official title:
Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) When Placed Within the Lower Eye Lid Canaliculus or Both the Upper and Lower Canaliculi for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Clinical Trial Summary

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel

Clinical Trial Description

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts, when placed within the lower eye lid canaliculus or both the upper and lower canaliculi for the treatment of pain, inflammation, and cystoid macular edema following 27 gauge vitrectomy with internal limiting membrane peel for the treatment of retinal edema associated with macular pucker ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04501367
Study type Interventional
Source Kovach Eye Institute
Contact Saad Ahmad, MD
Phone 6308339361
Email ifixretinas@gmail.com
Status Recruiting
Phase Phase 4
Start date April 27, 2021
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04409808 - IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device. N/A
Active, not recruiting NCT04566237 - Objective Measurements of the Opacification of the Lens After Vitrectomy N/A
Completed NCT00532415 - Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy Phase 3
Completed NCT04076072 - Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe N/A
Not yet recruiting NCT03633266 - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy N/A
Completed NCT00927628 - Macular Hole Reopening N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Terminated NCT01023009 - Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion
Completed NCT00737022 - Macular Appearance After Diabetic Vitrectomy N/A
Completed NCT02644694 - PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy Phase 1
Completed NCT03902795 - Functional and Morphological Results of Rhegmatogenous Retinal Detachment Treated With Vitrectomy
Completed NCT01319318 - Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy N/A
Not yet recruiting NCT04346095 - Oral Sedation in Vitreoretinal Surgery Phase 4
Completed NCT01159665 - The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) Phase 2
Completed NCT00685490 - Vitrectomy for Branch Retinal Vein Occlusion N/A
Completed NCT05446948 - Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy N/A
Completed NCT05710458 - Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter N/A
Terminated NCT02995746 - Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane N/A
Completed NCT03701542 - The Application of M-charts and Microperimetry for the Assessment of Visual Function in Patients After Vitrectomy Due to the Full Thickness Macular Hole.